WO2018134745A1 - Produit eutrophisant à usage cosmétique et utilisation relative - Google Patents

Produit eutrophisant à usage cosmétique et utilisation relative Download PDF

Info

Publication number
WO2018134745A1
WO2018134745A1 PCT/IB2018/050286 IB2018050286W WO2018134745A1 WO 2018134745 A1 WO2018134745 A1 WO 2018134745A1 IB 2018050286 W IB2018050286 W IB 2018050286W WO 2018134745 A1 WO2018134745 A1 WO 2018134745A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
base compound
eutrophicating
probiotic bacteria
family
Prior art date
Application number
PCT/IB2018/050286
Other languages
English (en)
Inventor
Alberto RODOLFI
Elisabetta CASELLI
Original Assignee
Copma S.C. A R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Copma S.C. A R.L. filed Critical Copma S.C. A R.L.
Publication of WO2018134745A1 publication Critical patent/WO2018134745A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria

Definitions

  • the present invention relates to the technical sector relating to cosmetic treatments for topical use, in the field of eutrophicating products having a nourishing and/or emollient and/or hydrating and/or moisturising and/or protective action.
  • the Applicant notes that there already exist detergent products on the free market, which contain probiotic bacteria of the Bacillus genus, with the aim of limiting the use of chemical disinfectants and facilitating a benign colonisation of the skin, so that the skin can combat pathogenic micro-organisms and render their population difficult.
  • the bacteria of the Bacillus genus represent a vast group of spore-forming Gram-positive bacteria, ubiquitous in nature and also present in the human intestine.
  • the spores formed by the Bacillus bacteria can survive for very long times, because of their resistance to desiccation, heat and many chemical substances, and are therefore ideal for probiotic applications in the field of cosmetics.
  • the presence of the probiotics further prevents re-colonisation by contaminant micro-organisms, thus stably maintaining hygiene where the probiotics are applied.
  • An aim of the present invention is to obviate the above drawbacks by providing a eutrophicating product for cosmetic use able to act rapidly and effectively against any potentially-dangerous microbial species, including those of the multi-resistant type.
  • the product for cosmetic use comprises the following compounds, in combination:
  • the base compound can be in the solid, liquid or gaseous state;the base compound can comprise: Cocoa butter, Butyrospermum Parkit Butter,
  • the probiotic bacteria spores are mixed with the base compound at a concentration comprised between 10 2 -10 9 spores/ml;
  • the bacteriophage elements are mixed with the base compound at a concentration comprised between 10 3 -10 9 PFU/ml;
  • the probiotic bacteria are of the Bacillus genus (preferably though not exclusively of the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus);
  • the bacteriophage elements comprise bacteriophages of the family Caudovirales and/or of the family Microviridae and/or of the family
  • Figures 1-3 are graphs relating to the reduction of the presence, over time (months), respectively of Staphylococcus aureus (Gram-positive bacterium), Enterobacteriaceae spp. (Gram-negative bacteria) and Candida albicans (fungus), on inert non-porous surfaces treated with product containing probiotic bacteria.
  • Staphylococcus aureus Gram-positive bacterium
  • Enterobacteriaceae spp. Gram-negative bacteria
  • Candida albicans fungus
  • Figures 4-6 are graphs relating to the reduction of the presence, over time (hours), respectively of Staphylococcus aureus, Enterobacteriaceae spp. and Candida albicans, on inert non-porous surfaces treated with product containing bacteriophages.
  • Figures 7-9 are graphs relating to the reduction of the presence, over time (weeks), respectively of Staphylococcus aureus, Enterobacteriaceae spp. and Candida albicans, on inert non-porous surfaces treated with product containing probiotic bacteria and bacteriophages.
  • Figure 10 is a graph relating to the reduction of the presence, over time (days), respectively of Staphylococcus aureus on inert non-porous surfaces treated with product simultaneously containing probiotic bacteria and bacteriophages, in which the synergic action can be appreciated with respect to those treated with only probiotic bacteria or only bacteriophages.
  • Figure 1 1 is a graph representing the reduction, after 24 hours, of the presence of Staphylococcus aureus on pig skin, treated with a eutrophicating product for cosmetic use containing only probiotics (PRO), only bacteriophages (BP) or a combination of probiotics and bacteriophages (PRO+BP).
  • the proposed eutrophicating product for cosmetic use innovatively comprises:
  • the invention also relates to a use of a eutrophicating product for cosmetic use, for treatment and protection of the skin and its adnexa.
  • the base compound can comprise one or more of the following: Cocoa butter, Butyrospermum Parkit Butter, Caprylyl Glycol, Carnauba, Cera Alba, Ceresin, Cetearyl Alcohol, Cetearyl Glucoside, Cetearyl Isononanoate, Ethylhexylmethoxycinnamate, Glyceril stearate citrate, Glycerin, Isopropryl Myristate, Lanolin, Panthenol, Paraffinum Liquidum, PEG-7 hydrogenated castor oil, Phenoxyethanol, Silicones, Sodium Carbomer, Sodium Carboxymethyl Betaglucan, Tocopheryl Acetate, Xanthana gum.
  • the probiotic bacteria spores are mixed with the base compound at a concentration comprised between 10 2 -10 9 spores/ml.
  • the bacteriophage elements specifically directed against bacteria potentially able to cause infection/inflammation of the skin or adnexa can be present in the base compound at a concentration comprised between 10 3 -10 9 spore/ml.
  • the probiotic bacteria can be of the Bacillus genus, including the species Bacillus subtilis, Bacillus megaterium and Bacillus pumilus.
  • the bacteriophage element can advantageously be selected, alternatively or in combination, according to the bacterial species to be contrasted, from among the following families: Caudovirales, Microviridae, Leviviridae, Inoviridae, Tectiviridae, Corticoviridae.
  • the bacteriophage elements of the Caudovirales family also comprise the Myoviridae, Siphoviridae, Podoviridae families.
  • the eutrophicating product of the invention for cosmetic use is particularly suitable for cleansing of the skin and the skin adnexa. It can be produced in the solid state and/or the paste state (for example for soaps, ointments, creams, gels etc.) or in the liquid state (for example lotions, milks, water-consistency liquids etc.) or in the gaseous state (for example for sprays etc.).
  • the action of the bacteriophages is specific, as specific types of lithic bacteriophages kill specific types of bacteria, and therefore perform a potentially very effective and specific action in the direct battle against undesired bacteria.
  • bacteriophages in products for cosmetic use is particularly indicated as they are rather stable in differing temperature conditions, pH and salinity of the environment, and can therefore be added to base compounds without suffering in terms of activity.
  • PCHS detergents containing probiotics has been amply evaluated on inert surfaces, where they have shown themselves to be able to destroy the microbial load by about 90% more with respect to traditional eutrophicating products, with daily use for about one month.
  • Figures 1 -3 illustrate the antimicrobial action (bacteria and fungi) of a detergent product based only on probiotics.
  • Figure 4-6 illustrate the anti-bacterial action of the bacteriophages on an inert surface contaminated by specific target bacteria.
  • the surfaces were contaminated with a known quantity of micro-organism (10 2 CFU/24 cm 2 ) and then treated by application of growing concentrations of specific bacteriophages (respectively 10 3 , 10 4 , 10 5 PFU), therefore in ratios of 10:1 , 100:1 and 1000:1 with the seeded target bacteria.
  • concentrations of specific bacteriophages (respectively 10 3 , 10 4 , 10 5 PFU), therefore in ratios of 10:1 , 100:1 and 1000:1 with the seeded target bacteria.
  • concentrations of specific bacteriophages respectively 10 3 , 10 4 , 10 5 PFU
  • the residual contamination was evaluated after 1 , 3, 6 hours by application of Rodac plates of specific medium for the indicated bacterial and fungi species.
  • the bacteriophages are able to remove more than 90% of the bacterial cells against which they are specifically directed.
  • the treatment with only bacteriophages has the limitation of being directed only against the bacteria specifically recognised by the bacteriophages, and therefore in a case of contamination by bacterial species different from those against which the bacteriophages are specifically directed, the surface treated remains contaminated by the species not attacked by the bacteriophages, as the bacteriophages are by definition specific for a bacterial species, and therefore not able to attack other bacterial species, nor are they able to attack species of fungi.
  • Figures 7-9 illustrate the effect of the combined and synergic antimicrobial action obtained with the contemporary presence of probiotic bacteria and bacteriophages on surfaces contaminated by the specific microbes illustrated.
  • the surfaces were contaminated with a known quantity of micro-organism (10 3 CFU/24 cm 2 ) and then treated by application of a solution containing probiotic bacteria (10 3 CFU/ml) and specific bacteriophages (10 4 PFU/ml).
  • Figure 10 illustrates the direct comparison between the antimicrobial action of the no. 3 treatments on the contamination by Staphyococcus aureus, measured in vitro on experimental models of inert surfaces of 24 cm 2 .
  • the surfaces were contaminated with a known quantity of micro-organism (10 3 CFU/24 cm 2 ) and then treated by application of a solution containing probiotic bacteria growing concentrations of (10 3 CFU/ml), only specific bacteriophages (10 4 PFU/ml), or the combination of probiotics and bacteriophages at the indicated concentrations.
  • the residual contamination was evaluated after 1 , 2, 3 and 7 hours by application of Rodac plates of specific medium for Staphyococcus aureus.
  • results are expressed as mean values ⁇ S.D. of samples in duplicate in three independent experiments. From the experimental tests carried out, it can easily be noted how the contemporaneous presence of Bacillus probiotics and anti-pathogen bacteriophages significantly increases the effectiveness of the destruction of the quantity on inert surfaces, thanks to the synergic action carried out against the various damaging micro-organisms.
  • the bacteriophages destroy the contaminant load extremely rapidly, but have a limited action over time and do not succeed in preventing re-contamination, nor can they attack bacterial species that are different from those specifically recognised.
  • probiotics reduce the contaminant load slowly but constantly, thanks to the competitive mechanisms, inhibiting recontamination and with an action that is independent of the microbial species present.
  • the contemporaneous presence of probiotics and bacteriophages guarantees the rapidity of the specific antimicrobial action and contemporaneous inhibition of recontamination, ensuring destruction of the pathogen that is rapid and stable over time.
  • composition of a eutrophicating product (creams, ointments), characterised by the presence of high concentrations of oily base substances, it is not at all out of the question for a mixture of probiotics and bacteriophages to act synergically on an organic surface that is irregular and porous such as the skin surface.
  • Bacteriophages in fact, due to their characteristic structure, might remain blocked internally of the oily matrix without being able to reach the surface of the target bacteria. Further, the same base compound might function as the source of carbon for the growth of the damaging microbial species.
  • Pig skin has relative characteristics (organic constitution, porosity, irregularity of the surface) that make it alike human skin. The test was carried out as described in the following.
  • Staphylococcus aureus was chosen as the reference microorganism for the tests carried out, as Staphylococci are part of the human cutaneous microbiota.
  • CTRb indicates base control; treatment with only eutrophicating base
  • CTR(+) indicates positive control; treatment with eutrophicating base to which a high-level disinfectant has been added 4.
  • PRO indicates treatment with eutrophicating base containing probiotics (10 5 CFU/ml)
  • BP indicates treatment with eutrophicating base containing bacteriophages (10 7 CFU/ml)
  • PRO+BP indicates treatment with eutrophicating base containing probiotics and bacteriophages (respectively 10 5 CFU/ml and 10 7 PFU/ml).
  • the treatment was carried out by the spreading of the flaps of skin on the surface, up to complete absorption.
  • the treat skin flaps were left to dry and then deposited on Baird-Parker agar medium plates, which enables growth and enumeration of the S. aureus residue CFU.
  • the presence of the bacteriophages thus represents an empowering of the anti-bacterial action of the product bases on only probiotic Bacillus as it facilitates and increases the action of the probiotics, which are also active on fungi.
  • the presence in the product of the invention of a greater number of families of bacteriophage families (Caudovirales, Microviridae, Leviviridae, Inoviridae, Tectiviridae and Corticoviridae) enables the product itself to have a bactericide activity on a broader group of treatable bacterial species.
  • the predetermined families of bacteriophage elements can be present in the product that is the object of the invention, both singly and in combination, so as to include the possibility of diversified treatments according to the specific need.
  • the eutrophicating product for cosmetic use of the invention having a nourishing and/or emollient and/or hydrating and/or moisturising and/or protective action, is able to act in a particularly rapid and effective way against any microbial species, including those of the multi- resistant type (superbugs).
  • the product is particularly effective for cosmetic treatment of the skin and skin adnexa.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un produit eutrophisant à usage cosmétique, comprenant : un composé de base présentant une action nourrissante et/ou émolliente et/ou hydratante et/ou humidifiante et/ou protectrice; des spores de bactéries probiotiques mélangées avec le composé de base; et comprenant aussi des éléments bactériophages mélangés avec le composé de base et présentant une activité bactéricide sur des espèces bactériennes non souhaitées prédéterminées présentes, les éléments bactériophages, en coopération avec les spores de bactéries probiotiques, étant capables de produire une action combinée et synergique contre des micro-organismes nuisibles. L'invention concerne également l'utilisation d'un produit eutrophisant pour le traitement et la protection de la peau et de ses annexes.
PCT/IB2018/050286 2017-01-19 2018-01-17 Produit eutrophisant à usage cosmétique et utilisation relative WO2018134745A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000005552A IT201700005552A1 (it) 2017-01-19 2017-01-19 Prodotto eutrofizzante per uso cosmetico
IT102017000005552 2017-01-19

Publications (1)

Publication Number Publication Date
WO2018134745A1 true WO2018134745A1 (fr) 2018-07-26

Family

ID=58779268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/050286 WO2018134745A1 (fr) 2017-01-19 2018-01-17 Produit eutrophisant à usage cosmétique et utilisation relative

Country Status (2)

Country Link
IT (1) IT201700005552A1 (fr)
WO (1) WO2018134745A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109182211A (zh) * 2018-10-16 2019-01-11 中国石油化工股份有限公司 宽温环境下防治srb的复合生物菌剂及使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013927A2 (fr) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Compositions topiques ameliorees contenant des bacteries probiotiques, des spores et des produits extra-cellulaires et leur utilisation
WO2014130540A1 (fr) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions et procédés de promotion de la croissance de microbes bénéfiques pour traiter ou prévenir une maladie ou prolonger la vie
WO2016170479A1 (fr) * 2015-04-22 2016-10-27 Copma S.C.A.R.L. Produit de nettoyage, d'assainissement et de désinfection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013927A2 (fr) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Compositions topiques ameliorees contenant des bacteries probiotiques, des spores et des produits extra-cellulaires et leur utilisation
WO2014130540A1 (fr) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions et procédés de promotion de la croissance de microbes bénéfiques pour traiter ou prévenir une maladie ou prolonger la vie
WO2016170479A1 (fr) * 2015-04-22 2016-10-27 Copma S.C.A.R.L. Produit de nettoyage, d'assainissement et de désinfection

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109182211A (zh) * 2018-10-16 2019-01-11 中国石油化工股份有限公司 宽温环境下防治srb的复合生物菌剂及使用方法
CN109182211B (zh) * 2018-10-16 2021-09-07 中国石油化工股份有限公司 宽温环境下防治srb的复合生物菌剂及使用方法

Also Published As

Publication number Publication date
IT201700005552A1 (it) 2018-07-19

Similar Documents

Publication Publication Date Title
Prabhakar et al. Evaluation of antimicrobial efficacy of Triphala (an Indian Ayurvedic herbal formulation) and 0.2% chlorhexidine against Streptococcus mutans biofilm formed on tooth substrate: An: in vitro: study
Kolhapure Evaluation of the antimicrobial efficacy and safety of PureHands herbal hand sanitizer in hand hygiene and on inanimate objects
JP2009519220A (ja) 病原体‐制御薬剤
US10683470B2 (en) Product for cleaning, sanitizing and hygienization
Neal et al. The efficacy of a toothbrush disinfectant spray—an in vitro study
Al-Zahrani et al. Evaluation of the efficiency of Non alcoholic-Hand Gel Sanitizers products as an antibacterial
Shabani et al. Antimicrobial activity of cinnamon oil against bacteria that cause skin infections
WO2018134745A1 (fr) Produit eutrophisant à usage cosmétique et utilisation relative
Kim et al. A fast and effective alternative to a high-ethanol disinfectant: Low concentrations of fermented ethanol, caprylic acid, and citric acid synergistically eradicate biofilm-embedded methicillin-resistant Staphylococcus aureus
Tweij-Thu-Alfeqar Razzaq et al. Sterilization of Surgical Tools: Removing Bacterial Endospores with a Combination of Povidone-iodine, Chlorhexidine Gluconate, Ethanol, and Methanol
Shaqra et al. Susceptibility of some bacterial contaminants recovered from commercial cosmetics in Jordan to preservatives and antibiotics
US11123579B2 (en) Detergent product for cosmetic use
JP2019509353A (ja) 微生物バイオフィルムに関連する皮膚状態および疾患の処置
Gorman et al. The sporicidal activity and inactivation of chlorhexidine gluconate in aqueous and alcoholic solution
Albureikan et al. Antibacterial activity of chloroxylenol and thymol against pathogenic bacteria isolated from under long nails
Ali et al. Evaluation of laboratory formulated hand sanitizing gel in riyadh municipality central area labs
EP1001738A1 (fr) Composition dermoprotectrice
Goroncy-Bermes Hand disinfection according to the European Standard EN 1500 (hygienic handrub): a study with Gram-negative and Gram-positive test organisms
US11877987B2 (en) Method for preparing an Eruca sativa extract and use for shaving
Singh et al. Comparative efficacy of disinfectant against routine lab bacterial contaminants
US20240131102A1 (en) Foam treatment method for bacteria
Eissa et al. Study of antimicrobial power of amphoteric disinfectants of Tego series used in pharmaceutical industry
KR102344582B1 (ko) 천연추출물을 포함하는 항바이러스용 조성물
Olorode et al. Antimicrobial activities of chlorhexidine gluconate and cetrimide against pathogenic microorganisms isolated from slaughter houses in Rivers State, Nigeria
Adegoke et al. Antimicrobial activities of some commercial cosmetics on selected cutaneous microflora

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18708199

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18708199

Country of ref document: EP

Kind code of ref document: A1